Abstract: A testing device and a testing method of a composite blade tilt rotor power assembly are related. The testing method includes the following steps: installing a tilt rotor flight power assembly on a flange platform of a testing device through a connector; confirming normal operation of an external power supply, the tilt rotor flight power assembly and a data acquisition computer; starting the tilt rotor flight power assembly, and controlling a tilt motor to rotate a cantilever shaft according to a tilt angle instruction; and recording the energy consumption and the tensile forces and torques in x, y and z directions of the tilt rotor flight power assembly by the data acquisition computer in real time.

Abstract: An antenna switching circuit, electronic device and method. The switching circuit includes a radio frequency processor, a radio frequency front-end, a first switch, and an antenna system with a plurality of antennas. The radio frequency processor receives a first radio frequency signal, generates a second radio frequency signal based on a loss value of the first switch, and transmits the second radio frequency signal to the first switch. The first switch selects, from a plurality of radio frequency channels in the radio frequency front-end, a radio frequency channel coupled with the radio frequency processor, and transmits the second radio frequency signal to a radio frequency channel. The radio frequency front-end receives and processes the second radio frequency signal to generate a third radio frequency signal and transmits it to the antenna system, which outputs the third radio frequency signal.

Abstract: The present application relates to a gRNA targeting polypeptide 2, subfamily V, family 4, cytochrome P450 (CYP4V2) gene. The present application also relates to a donor nucleic acid molecule comprising a human CYP4V2 nucleotide sequence. The present application further relates to use of the gRNA and the donor nucleic acid molecule in the treatment of Bietti crystalline dystrophy.

Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Abstract: The invention discloses a total extract of Fructus Cnidii, which contains bergamot, the application of the total extract of Fructus Cnidii in preparing medicines for preventing and/or treating allergic dermatosis, psoriasis or herpes zoster, and the construction method of the fingerprint of the total extract of Fructus Cnidii. The invention adopts LC-MS technology to establish the fingerprint of the total extract of Fructus Cnidii, thus effectively improving the quality stability, uniformity and controllability of the total extract of Fructus Cnidii.

Abstract: The present application relates to a vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector described herein has a good expression effect, high expression speed, and more stable expression intensity. The present application also provides cells, pharmaceutical compositions, and kits comprising the vector, and methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.

Abstract: The present application relates to a gRNA targeting CYP4V2 gene, and a donor nucleic acid molecule comprising a CYP4V2 gene fragment. The present application also relates to use of the gRNA and the donor nucleic acid molecule in the preparation of a medicament for treating Bietti crystalline dystrophy.

Abstract: The present application relates to the use of CYP4V2 and RdCVF in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy. The present application also relates to an isolated nucleic acid molecule comprising a polynucleotide encoding CYP4V2 and a polynucleotide encoding RdCVF. The present application also relates to an amino acid sequence encoded by the isolated nucleic acid molecule, a vector comprising the isolated nucleic acid molecule, and a cell comprising the nucleic acid or the vector as well as use thereof in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.

Abstract: A vector includes a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector has a good expression effect, high expression speed, and more stable expression intensity. Cells, pharmaceutical compositions, and kits can include the vector. Methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy can include administering the vector to a subject.

Abstract: A metal-organic framework (MOF) MIL-125 and a preparation method and a use thereof are provided. The MOF MIL-125 is a round cake-like crystal and has an external specific surface area (SSA) of 160 m2/g to 220 m2/g. The MOF MIL-125 provided in the present application has a large number of microporous structures, a large external SSA, and a high catalytic activity in oxidation.

Abstract: An adsorbent and a use thereof are provided. The adsorbent is a metal-organic framework (MOF) MIL-125; the MOF MIL-125 has an external specific surface area (SSA) of 160 m2/g to 220 m2/g; and the MOF MIL-125 includes a micropore with an area of 1,000 m2/g to 1,500 m2/g. The external SSA of the MOF MIL-125 is much higher than an external SSA of the traditional MIL-125, which has promising application prospects in the adsorptive separation of xylene isomers and exhibits high selectivity for p-xylene.

Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Abstract: A molten-state suspended ellipsoidal droplet image processing algorithm is based on dual-camera vision. The algorithm includes acquiring images of a standard sphere by means of two cameras, and calculating the actual size corresponding to each individual pixel of the two standard sphere images; synchronously acquiring two images of a droplet by using the two cameras at a specified included angle; establishing an ellipsoidal quadric surface equation for the droplet, respectively detecting edge contour lines of the two images, and establishing elliptical contour line equations for the edge contour lines; introducing a specified included angle, and constructing an equation set according to relationships between parameters of the two elliptical contour line equations and the ellipsoidal quadric surface equation; solving the equation set to obtain the length of each semi-axis of the droplet; and calculating the volume of the droplet according to the length of each semi-axis.

Abstract: The subject application relates to a method for treating retinitis pigmentosa, comprising the step of: enabling a subject in need thereof to have a functional RHO gene, wherein the functional RHO gene does not comprise a mutation site selected from the group consisting of c.C50T and c.C403T. The subject application also relates to a method for editing the RHO gene, and a composition for treating retinitis pigmentosa in a subject.

Abstract: The present application relates to the use of CYP4V2 and RdCVF in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy. The present application also relates to an isolated nucleic acid molecule comprising a polynucleotide encoding CYP4V2 and a polynucleotide encoding RdCVF. The present application also relates to an amino acid sequence encoded by the isolated nucleic acid molecule, a vector comprising the isolated nucleic acid molecule, and a cell comprising the nucleic acid or the vector as well as use thereof in the manufacture of a medicament for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.

Abstract: The present disclosure relates to dimeric STING agonists of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof. The present disclosure also relates to methods of preparing the compounds and methods of using the compounds.

Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.